Advertisement

Topics

EMA approval for adalimumab biosimilars Idacio and Kromeya

06:41 EST 8 Feb 2019 | Generics and Biosimilars Initiative

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 31 January 2019 that it had recommended granting marketing authorization for the adalimumab biosimilars Idacio and Kromeya.

Original Article: EMA approval for adalimumab biosimilars Idacio and Kromeya

NEXT ARTICLE

More From BioPortfolio on "EMA approval for adalimumab biosimilars Idacio and Kromeya"

Advertisement
Quick Search
Advertisement
Advertisement